Bayesian interim analysis of phase II cancer clinical trials

Statistics in Medicine

Volumn 16, Issue 16, 1997, Pages 1791-1802

  Heitjan, Daniel F ^a  

^a Columbia School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PROBABILITY; STANDARD; STATISTICS;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; CLINICAL TRIALS, PHASE II; CYTARABINE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MODELS, STATISTICAL; RESEARCH DESIGN; VIDARABINE;

EID: 0030767683     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19970830)16:16<1791::AID-SIM609>3.0.CO;2-E     Document Type: Article

References (20)

1. Gehan, E. A. 'The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent', Journal of Chronic Diseases, 13, 346-353 (1961).
2. Herson, J. 'Predictive probability early termination plans for phase II clinical trials', Biometrics, 35, 775-783 (1979).
3. Lee, Y. J., Staquet, M., Simon, R., Catane, R. and Muggia, F. 'Two-stage plans for patient accrual in phase II cancer clinical trials', Cancer Treatment Reports, 63, 1721-1726 (1979).
4. Fleming, T. R. 'One-sample multiple testing procedure for phase II clinical trials', Biometrics, 38, 143-151 (1982).
5. Mehta, C. R. and Cain, K. C. 'Charts for the early stopping of pilot studies', Journal of Clinical Oncology, 2, 676-682 (1984).
6. Chang, M., Therneau, T. M., Wieand, H. S. and Cha, S. S. 'Designs for group sequential phase II clinical trials', Biometrics, 43, 865-874 (1987).
7. Sylvester, R. J. 'A Bayesian approach to the design of phase II clinical trials', Biometrics, 44, 823-826 (1988).
8. Simon, R. 'Optimal two-stage designs for phase II clinical trials', Controlled Clinical Trials, 10, 1-10 (1989).
9. Bellissant, E., Benichou, J. and Chastang, C. 'Application of the triangular test to phase II cancer clinical trials', Statistics in Medicine, 9, 907-917 (1990).
10. Green, S. J. and Dahlberg, S. 'Planned versus attained design in phase II clinical trials', Statistics in Medicine, 11, 853-862 (1992).
11. Storer, B. E. 'A class of phase II designs with three possible outcomes', Biometrics, 48, 55-60 (1992).
12. Thall, P. F. and Estey, E. H. 'A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation', Statistics in Medicine, 12, 1197-1211 (1993).
13. Thall, P. F. and Simon, R. 'Practical Bayesian guidelines for phase IIB clinical trials', Biometrics, 50, 337-349 (1994).
14. Bryant, J. and Day, R. 'Incorporating toxicity considerations into the design of two-stage phase II clinical trials', Biometrics, 51, 1372-1383 (1995).
15. Conaway, M. R. and Petroni, G. R. 'Bivariate sequential designs for phase II trials', Biometrics, 51, 656-664 (1995).
16. Weiss, G. B. and Hokanson, J. A. 'Optimal phase II trials', Biometrics, 44, 910-911 (1988).
17. Freedman, L. S., Spiegelhalter, D. J. and Parmar, M. K. B. 'The what, why and how of Bayesian clinical trials monitoring', Statistics in Medicine, 13, 1371-1383 (1994).
18. Heitjan, D. F., Houts, P. S. and Harvey, H. A. 'A decision-theoretic evaluation of early stopping rules', Statistics in Medicine, 11, 673-683 (1992).
19. Lewis, R. J. and Berry, D. A. 'Group sequential clinical trials: A classical evaluation of Bayesian decision-theoretic designs', Journal of the American Statistical Association, 89, 1528-1534 (1994).
20. Thall, P. F. and Simon, R. 'Incorporating historical control data in planning phase II clinical trials', Statistics in Medicine, 9, 215-228 (1990).